BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 15889234)

  • 1. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
    Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
    Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Betteridge DJ; Vergès B
    Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes.
    Seufert J; Urquhart R
    Diabetes Res Clin Pract; 2008 Mar; 79(3):453-60. PubMed ID: 18160120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
    Lawrence JM; Reid J; Taylor GJ; Stirling C; Reckless JP
    Diabetes Care; 2004 Jan; 27(1):41-6. PubMed ID: 14693964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
    Charbonnel B; Roden M; Urquhart R; Mariz S; Johns D; Mihm M; Widel M; Tan M
    Diabetologia; 2005 Mar; 48(3):553-60. PubMed ID: 15739120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.
    Roden M; Mariz S; Brazzale AR; Pacini G
    J Intern Med; 2009 Apr; 265(4):476-87. PubMed ID: 19298459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).
    Scheen AJ; Tan MH; Betteridge DJ; Birkeland K; Schmitz O; Charbonnel B;
    Diabet Med; 2009 Dec; 26(12):1242-9. PubMed ID: 20002476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study.
    Matthews DR; Charbonnel BH; Hanefeld M; Brunetti P; Schernthaner G
    Diabetes Metab Res Rev; 2005; 21(2):167-74. PubMed ID: 15386821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
    Charpentier G; Halimi S;
    Diabetes Obes Metab; 2009 Sep; 11(9):844-54. PubMed ID: 19614944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.
    Rajagopalan R; Perez A; Ye Z; Khan M; Murray FT
    Drugs Aging; 2004; 21(4):259-71. PubMed ID: 15012171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
    Pareek A; Chandurkar N; Thomas N; Viswanathan V; Deshpande A; Gupta OP; Shah A; Kakrani A; Bhandari S; Thulasidharan NK; Saboo B; Devaramani S; Vijaykumar NB; Sharma S; Agrawal N; Mahesh M; Kothari K
    Curr Med Res Opin; 2014 Jul; 30(7):1257-66. PubMed ID: 24669876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
    Bolli G; Dotta F; Colin L; Minic B; Goodman M
    Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17).
    Scheen AJ; Tan MH; Betteridge DJ; Birkeland K; Schmitz O; Charbonnel B;
    Diabet Med; 2009 Oct; 26(10):1033-9. PubMed ID: 19900236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term glycaemic control with pioglitazone in patients with type 2 diabetes.
    Campbell IW
    Int J Clin Pract; 2004 Feb; 58(2):192-200. PubMed ID: 15055868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.
    Belcher G; Lambert C; Edwards G; Urquhart R; Matthews DR
    Diabetes Res Clin Pract; 2005 Oct; 70(1):53-62. PubMed ID: 16002175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.
    Perriello G; Pampanelli S; Di Pietro C; Brunetti P;
    Diabet Med; 2006 Mar; 23(3):246-52. PubMed ID: 16492206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
    Hanefeld M; Brunetti P; Schernthaner GH; Matthews DR; Charbonnel BH;
    Diabetes Care; 2004 Jan; 27(1):141-7. PubMed ID: 14693980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.